Jack Nathan Medical Past Earnings Performance
Past criteria checks 0/6
Jack Nathan Medical's earnings have been declining at an average annual rate of -9.8%, while the Healthcare industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 40.2% per year.
Key information
-9.8%
Earnings growth rate
3.2%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 40.2% |
| Return on equity | n/a |
| Net Margin | -38.5% |
| Last Earnings Update | 30 Apr 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Jack Nathan Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 24 | 20 | -8 | 20 | 0 |
| 31 Jan 24 | 19 | -7 | 18 | 0 |
| 31 Oct 23 | 17 | -8 | 17 | 0 |
| 31 Jul 23 | 17 | -7 | 16 | 0 |
| 30 Apr 23 | 16 | -6 | 16 | 0 |
| 31 Jan 23 | 15 | -7 | 17 | 0 |
| 31 Oct 22 | 16 | -6 | 16 | 0 |
| 31 Jul 22 | 14 | -7 | 15 | 0 |
| 30 Apr 22 | 12 | -8 | 14 | 0 |
| 31 Jan 22 | 10 | -8 | 12 | 1 |
| 31 Oct 21 | 6 | -7 | 9 | 1 |
| 31 Jul 21 | 5 | -14 | 7 | 0 |
| 30 Apr 21 | 4 | -11 | 5 | 0 |
| 31 Jan 21 | 4 | -10 | 4 | 0 |
| 31 Oct 20 | 4 | -9 | 3 | 0 |
| 31 Jul 20 | 4 | 0 | 2 | 0 |
| 30 Apr 20 | 4 | -2 | 2 | 0 |
| 31 Jan 20 | 4 | -1 | 3 | 0 |
| 31 Jan 19 | 3 | 2 | 1 | 0 |
Quality Earnings: JNHM.F is currently unprofitable.
Growing Profit Margin: JNHM.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JNHM.F is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare JNHM.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JNHM.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).
Return on Equity
High ROE: JNHM.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.